{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:43:13Z","timestamp":1783453393428,"version":"3.55.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody-based immunotherapies have revolutionized leukemia and lymphoma treatment, with animal studies being crucial in evaluating effectiveness and side effects. By targeting the evolutionary conserved Slamf7 immune receptor, which is naturally expressed by the murine multiple myeloma cell line MPC-11, we have developed a syngeneic mouse model for direct comparison of 3 immunotherapies: monoclonal antibodies (mAb), bispecific T-cell engagers (BiTE), and chimeric antigen receptor (CAR) T cells (CART), all targeting Slamf7. Slamf7-BiTE is a bispecific single-chain antibody consisting of \u03b1-Slamf7 and \u03b1-CD3 Fv fragments joined through a Gly-Ser linker, and Slamf7-CART comprises the \u03b1-Slamf7 Fv fragment fused to the msCD8\u03b1 transmembrane and msCD28, 4-1BB, and CD3\u03b6 intracellular signaling domains. Slamf7-BiTE and Slamf7-CART effectively killed MPC-11 cells in\u00a0vitro, independently of Slamf7-mediated inhibitory signaling by self-ligation. After chimerizing the constant region of the rat\u2013anti-mouse Slamf7 antibody to mouse Fc-immunoglobulin G2a for enhanced effector functions, Slamf7-mAb triggered antigen-specific antibody-dependent cellular cytotoxicity by binding to Fc\u03b3 receptor IV. In\u00a0vivo, all 3 immunotherapies showed antitumor effects against Slamf7-expressing targets. Unlike Slamf7-mAb, Slamf7-BiTE led to considerable side effects in test animals, including weight loss and general malaise, which were also observed to a lesser extent after Slamf7-CART infusion. In allogeneic transplant, Slamf7-BiTE and Slamf7-CART maintained activity compared with the nontransplant setting, whereas Slamf7-mAb displayed enhanced antimyeloma activity. In summary, our model faithfully replicates treatment efficacy and side effects detected after human immunotherapy. It aids in developing and improving immunotherapies and may help devise novel approaches to mitigate undesired effects in steady state and allogeneic stem cell transplantation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011647","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T16:09:01Z","timestamp":1704902941000},"page":"1934-1945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model"],"prefix":"10.1182","volume":"8","author":[{"given":"Karin","family":"Frebel","sequence":"first","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-7250","authenticated-orcid":false,"given":"J\u00f6rn C.","family":"Albring","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Wohlgemuth","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schw\u00f6ppe","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Hailfinger","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"5","key":"2024042313310087700_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2024042313310087700_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"issue":"5891","key":"2024042313310087700_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"6230","key":"2024042313310087700_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"6382","key":"2024042313310087700_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"2","key":"2024042313310087700_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"issue":"2","key":"2024042313310087700_bib7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024042313310087700_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2024042313310087700_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","article-title":"Humanized immune system mouse models: progress, challenges and opportunities","volume":"20","author":"Allen","year":"2019","journal-title":"Nat Immunol"},{"issue":"6","key":"2024042313310087700_bib10","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1073\/pnas.1019524108","article-title":"Human thrombopoietin knockin mice efficiently support human hematopoiesis in\u00a0vivo","volume":"108","author":"Rongvaux","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024042313310087700_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2018.12.013","article-title":"Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia","volume":"39","author":"Jin","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"2024042313310087700_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model [published correction appears in Nat Biotechnol. 2017;35(12):1211]","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2024042313310087700_bib13","first-page":"15.21.1","article-title":"Creation of \"humanized\" mice to study human immunity","volume":"Chapter 15","author":"Pearson","year":"2008","journal-title":"Curr Protoc Immunol"},{"issue":"11","key":"2024042313310087700_bib14","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2010-08-301507","article-title":"Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-granulocyte-macrophage colony-stimulating factor-and interleukin-3-expressing NOD-SCID IL2R\u03b3(null) humanized mice","volume":"117","author":"Billerbeck","year":"2011","journal-title":"Blood"},{"key":"2024042313310087700_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jim.2014.02.011","article-title":"Generation of improved humanized mouse models for human infectious diseases","volume":"410","author":"Brehm","year":"2014","journal-title":"J\u00a0Immunol Methods"},{"issue":"5","key":"2024042313310087700_bib16","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"2024042313310087700_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pathol-052016-100332","article-title":"Humanized mouse models of clinical disease","volume":"12","author":"Walsh","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"2024042313310087700_bib18","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2024042313310087700_bib19","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024042313310087700_bib20","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024042313310087700_bib21","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2024042313310087700_bib22","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2024042313310087700_bib23","first-page":"81","article-title":"Cloning cDNA ends using RACE","volume":"13","author":"Zhang","year":"1998","journal-title":"Methods Mol Med"},{"key":"2024042313310087700_bib24","first-page":"56","volume-title":"Antibody Engineering","author":"Bradbury","year":"2010"},{"issue":"5","key":"2024042313310087700_bib25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1073\/pnas.84.5.1374","article-title":"Identification of a monoclonal antibody specific for a murine T3 polypeptide","volume":"84","author":"Leo","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2024042313310087700_bib26","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A\u00a0small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2024042313310087700_bib27","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2024042313310087700_bib28","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2024042313310087700_bib29","doi-asserted-by":"crossref","first-page":"e20192203","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J\u00a0Exp Med"},{"issue":"3915","key":"2024042313310087700_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.167.3915.186","article-title":"Immunoglobulin production: method for quantitatively detecting variant myeloma cells","volume":"167","author":"Coffino","year":"1970","journal-title":"Science"},{"issue":"7","key":"2024042313310087700_bib31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00262-005-0082-x","article-title":"Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3","volume":"55","author":"Schlereth","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2024042313310087700_bib32","doi-asserted-by":"crossref","first-page":"22345","DOI":"10.1038\/s41598-020-79303-0","article-title":"A\u00a0simple method using CRISPR-Cas9 to knock-out genes in murine cancerous cell lines","volume":"10","author":"Ishibashi","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"2024042313310087700_bib33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.4049\/jimmunol.155.3.1544","article-title":"An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity","volume":"155","author":"Alegre","year":"1995","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"2024042313310087700_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0161-5890(95)00087-9","article-title":"A\u00a0single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL","volume":"33","author":"Jost","year":"1996","journal-title":"Mol Immunol"},{"key":"2024042313310087700_bib35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3389\/fimmu.2017.00793","article-title":"The affinity of elongated membrane-tethered ligands determines potency of T cell receptor triggering","volume":"8","author":"Chen","year":"2017","journal-title":"Front Immunol"},{"issue":"11","key":"2024042313310087700_bib36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and biology of relapse after stem cell transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024042313310087700_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024042313310087700_bib38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2003-10-3387","article-title":"Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets","volume":"104","author":"Stelljes","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2024042313310087700_bib39","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/eji.202149181","article-title":"Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies","volume":"51","author":"Nouveau","year":"2021","journal-title":"Eur J Immunol"},{"issue":"3","key":"2024042313310087700_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"issue":"11","key":"2024042313310087700_bib41","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41590-022-01337-5","article-title":"Divergent clonal differentiation trajectories of T cell exhaustion","volume":"23","author":"Daniel","year":"2022","journal-title":"Nat Immunol"},{"issue":"12","key":"2024042313310087700_bib42","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1084\/jem.20102017","article-title":"Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression","volume":"207","author":"Albring","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2024042313310087700_bib43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2002-06-1751","article-title":"Revealing lymphoma growth and the efficacy of immune cell therapies using in\u00a0vivo bioluminescence imaging","volume":"101","author":"Edinger","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2024042313310087700_bib44","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10428190902943077","article-title":"Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab","volume":"50","author":"Nagorsen","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2024042313310087700_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A\u00a0comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2024042313310087700_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2024042313310087700_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024042313310087700_bib48","doi-asserted-by":"crossref","first-page":"640954","DOI":"10.3389\/fgene.2021.640954","article-title":"Animal models of multiple myeloma bone disease","volume":"12","author":"Mehdi","year":"2021","journal-title":"Front Genet"},{"issue":"2","key":"2024042313310087700_bib49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2024042313310087700_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/cancers14010055","article-title":"Allogeneic stem cell transplantation in multiple myeloma","volume":"14","author":"Greil","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2024042313310087700_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024042313310087700_bib52","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2024042313310087700_bib53","first-page":"1344","article-title":"The calm after the cytokine storm: lessons from the TGN1412 trial [published correction appears in J Clin Invest. 2008;118(6):2365","volume":"118","author":"St Clair","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024042313310087700_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1934\/2222843\/blooda_adv-2023-011647-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1934\/2222843\/blooda_adv-2023-011647-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:31:29Z","timestamp":1713879089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1934\/507107\/Comparison-of-antibody-based-immunotherapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011647","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}